ABCB1 genotype and clinically relevant bleeding risk during extended anticoagulation therapy for pulmonary embolism: a two-phase study
Research and Practice in Thrombosis and Haemostasis · 2026
DOI: 10.1016/j.rpth.2026.106925 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Research and Practice in Thrombosis and Haemostasis, 2026. Verfasst von Zhu Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respir…. Hauptthemen laut MEDLINE: Pulmonary Embolism, Hemorrhage, Polymorphism, Single Nucleotide, Rivaroxaban. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
Background
Extended direct oral anticoagulant (DOAC) therapy reduces recurrent venous thromboembolism, but clinically relevant bleeding (CRB) remains a safety concern. DOACs exhibit substantial pharmacokinetic variability among individuals, and genetic determinants of bleeding risk during extended anticoagulation remain unclear.
Objectives
To explore the association between pharmacogenomic variants and CRB during extended rivaroxaban therapy and explore their potential contribution to bleeding risk prediction in patients with pulmonary embolism (PE).
Methods
In phase 1, 633 rivaroxaban-treated PE patients from the multicenter registry with genome-wide genotyping data were included. Thirteen candidate single-nucleotide polymorphisms across 9 genes previously reported to influence DOAC pharmacokinetics were assessed for associations with CRB during extended anticoagulation. In phase 2, 101 PE patients from an independent cohort underwent rivaroxaban plasma concentration measurement and genotyping for pharmacokinetic validation.
Results
In phase 1, 70 patients (11.1%) experienced CRB during the 1-year follow-up. Three ABCB1 variants showed nominal associations with CRB; none remained significant after study-wide false discovery rate correction (adjusted P = .074), although they met the gene-level false discovery rate threshold (adjusted P = .030). Among these, rs1045642 was also associated with dose-normalized peak plasma concentration in phase 2 (P = .001), without affecting recurrent venous thromboembolism or mortality. In phase 2, ABCB1 rs1045642 TT carriers had significantly higher dose-normalized peak concentrations (P = .001). Incorporating rs1045642 into 5 established bleeding scores (Kuijer, RIETE, VTE-BLEED, PE-SARD and VTE-PREDICT) consistently improved reclassification (category-free net reclassification improvement, 0.214-0.312; integrated discrimination improvement, 0.022-0.035), although the corresponding improvements in area under the receiver operating characteristic curve did not reach statistical significance.
Conclusion
ABCB1 rs1045642 showed a nominal association with CRB and higher rivaroxaban peak plasma concentration during extended therapy. Adding this genotype to existing bleeding scores improved risk reclassification but not overall discrimination, and its clinical utility requires independent prospective validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Department of Pulmo…
- Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, China.
- Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Harbin Medical University, Harbin, China.
- Department of Pharmacy, China-Japan Friendship Hospital, Beijing, China.
Förderung
- Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
Zitieren
APA
Zhang, Z., Li, H., Zou, B., Ji, X., Zhang, Y., Tao, Y., Xi, L., Li, K., Li, H., Duo, M., Zhao, L., Zuo, X., Zhai, Z., Wang, C., & CURES investigators (2026). ABCB1 genotype and clinically relevant bleeding risk during extended anticoagulation therapy for pulmonary embolism: a two-phase study. Research and Practice in Thrombosis and Haemostasis. https://doi.org/10.1016/j.rpth.2026.106925
Vancouver
Zhang Z, Li H, Zou B, Ji X, Zhang Y, Tao Y, et al. ABCB1 genotype and clinically relevant bleeding risk during extended anticoagulation therapy for pulmonary embolism: a two-phase study. Research and Practice in Thrombosis and Haemostasis. 2026. doi:10.1016/j.rpth.2026.106925
BibTeX
@article{Zhang2026,
author = {Zhang, Zhu and Li, Haobo and Zou, Bingzhang and Ji, Xiaofan and Zhang, Yu and Tao, Yuzhi and Xi, Linfeng and Li, Kuangxun and Li, Huiwen and Duo, Mengjie and Zhao, Li and Zuo, Xianbo and Zhai, Zhenguo and Wang, Chen and CURES investigators, CURES investigators},
title = {ABCB1 genotype and clinically relevant bleeding risk during extended anticoagulation therapy for pulmonary embolism: a two-phase study},
journal = {Research and Practice in Thrombosis and Haemostasis},
year = {2026},
doi = {10.1016/j.rpth.2026.106925}
}
EUVIMED